Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.
Blog Posts
340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities
…
SPONSORED CONTENT
It is my pleasure to introduce our company to 340B Report’s readers. RxPreferred Benefits is a fully transparent 340B Administrator and Pharmacy Benefit Manager (PBM) founded, and solely owned, by independent pharmacy representatives. Privately held and headquartered in Nashville, TN, RxPreferred operates nationally, partnering with a wide range of clients including: 340B covered entities, self-funded employers, hospitals, health systems, hospices, pharmacies, brokers, and third-party administrators.
Zero Conflicts-of-Interest
…
A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.
Please Login or Become a Paid Subscriber to View this
Attorneys for the government and drug manufacturer Eli Lilly dueled over legality of 340B contract pharmacy requirements during a hearing before a federal district judge in Indianapolis today.
Please Login or Become a Paid Subscriber to
An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View
AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit, this round focused on the government’s May 17 letter telling the company its contract pharmacy actions are illegal.
…SPONSORED CONTENT
Verity Solutions, the award-winning provider of 340B software and services, is releasing their next “Experience Verity 340B” webinar series on August 3-5, 2021.
Each 20-30 minute sessions is designed for anyone who wants to understand how their Covered Entity’s 340B program performance might be enhanced by Verity Solutions’ unique blend of cutting-edge software technology and advanced account management. Verity 340B industry experts will cover each
…
The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform
…